June 29, 2021
June 29, 2021
Dave Kelleher spoke with Fierce Biotech about its recent $230 million funding, and how it's going to help fuel the companies growth into new regions and clinical trials.
Three decades after becoming friends at Duke University and after years of running separate consulting firms, Ed Tourtellotte and David Kelleher came together in late 2015 to bring to fruition a tech company to help support clinical trials for diseases that had personally affected them.
Now, their company, 4G Clinical, has snagged more than $230 million in funding from Goldman Sachs Asset Management to expand their randomization and trial supply management (RTSM) technology further into the Asia Pacific region and into more clinical trials.
Kelleher and Tourtellotte were not going to return to school for Ph.D.s in biochemistry to discover new molecules, but they wanted a way to help with the development of treatments for diseases such as multiple sclerosis and triple-negative breast cancer, which have impacted the co-founders' families, CEO Kelleher told Fierce Biotech...
Amy Ripston, 4G Clinical Vice President of Marketing, has over 20 years of B2B experience, of which she spent 9 years in the bio/pharmaceutical industry. Amy has a knack for identifying market trends, synthesizing content, engaging thought leaders, and connecting businesses with innovative solutions.